SEC Comment Letter for Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771) (HEPA) — May 28, 2019
Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771)
Date: May 28, 2019 · CIK: 0001583771 · Accession: 0000000000-19-008945
AI Filing Summary & Sentiment
File numbers found in text: 333-231604
Letter
May 24, 2019 Robert Foster President and Chief Executive Officer ContraVir Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, NJ 08837 Re:ContraVir Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed May 20, 2019 File No. 333-231604 Dear Dr. Foster: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Jeffrey J. Fessler, Esq.
Show Raw Text
May 24, 2019
Robert Foster
President and Chief Executive Officer
ContraVir Pharmaceuticals, Inc.
399 Thornall Street, First Floor
Edison, NJ 08837
Re:ContraVir Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed May 20, 2019
File No. 333-231604
Dear Dr. Foster:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Jeffrey J. Fessler, Esq.